Antiviral Activity of Electrospun Polyamide Ultrathin Fibers Against SARS-CoV-2 Variant.

Publication date: Feb 04, 2025

The development of new strategies to produce nanomaterials that can be used as personal protective equipment with antiviral activity and low toxicity is crucial. Electrospun ultrathin fibers have attracted considerable attention due to their potential for biomedical applications, including antiviral activity. Herein, we electrospun different grades of commercially available polyamide to produce ultrathin fibers and investigate their antiviral activity against SARS-CoV-2 Gamma lineage (P. 1). We evaluated the morphology, chemical composition, and mechanical properties of the ultrathin fibers. We also investigated the in vitro cytotoxicity, hemolytic activity, and antiviral activity against SARS-CoV-2 Gamma lineage (P. 1) of the developed ultrathin fibers. The ultrathin fibers had the following diameters and elastic moduli: (i) unmodified crude ultrathin polyamide (PAP) 0. 59 μm and 3 MPa, (ii) polyamide Biotech (PAAM) 0. 74 μm and 2. 2 MPa, and (iii) Amni Virus-Bac OFF polyamide (PAVB) 0. 69 μm and 1. 06 MPa. The ultrathin PAP fibers showed increased antiviral activity compared to the other ultrathin fibers (PAAM and PAVB). None of the electrospun fibers showed cytotoxicity at the lowest concentration (12. 5%). Additionally, hemolysis tests demonstrated a nonhemolytic profile for all fiber groups, reinforcing their biocompatibility and suitability for biomedical applications. The antiviral properties of the electrospun ultrathin PAP fibers, combined with their noncytotoxic and nonhemolytic characteristics, highlight their potential to be used as personal protection against SARS-CoV-2.

Open Access PDF

Concepts Keywords
Antiviral Activity
Attracted Antiviral
Biocompatibility Applications
Hemolysis Biomedical
Nanomaterials Cov
Electrospun
Fibers
Mpa
Pap
Polyamide
Potential
Produce
Sars
Ultrathin

Semantics

Type Source Name
drug DRUGBANK Medroxyprogesterone acetate
disease MESH hemolysis
disease MESH COVID 19 pandemic
drug DRUGBANK p-Phenylenediamine
disease IDO production
disease IDO bactericidal
disease IDO bacteria
drug DRUGBANK Medical air
disease MESH physical barrier
drug DRUGBANK Microcrystalline cellulose
disease MESH respiratory diseases
disease IDO process
drug DRUGBANK Gold
drug DRUGBANK Nitrogen
disease IDO cell
drug DRUGBANK Proline
drug DRUGBANK Ribostamycin
drug DRUGBANK Streptomycin
drug DRUGBANK Amphotericin B
disease IDO assay
drug DRUGBANK Phenol
drug DRUGBANK Dimethyl sulfoxide
disease IDO blood
drug DRUGBANK Water
drug DRUGBANK Isoxaflutole
disease MESH defects
drug DRUGBANK Albendazole
disease MESH weight loss
disease MESH death
drug DRUGBANK Diethyltoluamide
drug DRUGBANK Coenzyme M
disease MESH Dengue
disease MESH Emergency
drug DRUGBANK Etoperidone
drug DRUGBANK Nonoxynol-9
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Zinc
disease MESH Influenza
drug DRUGBANK Alginic acid
drug DRUGBANK Polyvinyl alcohol
drug DRUGBANK Troleandomycin
drug DRUGBANK Centella asiatica
drug DRUGBANK Silver
drug DRUGBANK Methylene blue
drug DRUGBANK Selenium
disease MESH Neuroblastoma
drug DRUGBANK Tretamine
drug DRUGBANK Methylergometrine
drug DRUGBANK Activated charcoal
drug DRUGBANK Flunarizine
drug DRUGBANK Hexadecanal

Original Article

(Visited 1 times, 1 visits today)